Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – What’s Next?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) gapped down prior to trading on Thursday. The stock had previously closed at $15.16, but opened at $14.10. Ono Pharmaceutical shares last traded at $14.10, with a volume of 1,000 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 4th. One research analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

Ono Pharmaceutical Stock Performance

The stock has a market cap of $6.63 billion, a P/E ratio of 12.48 and a beta of 0.38. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.86 and a current ratio of 3.28. The firm’s fifty day simple moving average is $15.14 and its 200-day simple moving average is $14.87.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.